← Back to Clinical Trials
Recruiting NCT04459806

NCT04459806 Intracranial PrEssure Time dOse (ImPETO)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04459806
Status Recruiting
Phase
Sponsor University of Milano Bicocca
Condition Intracranial Hypertension
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2023-11-13
Primary Completion 2026-11-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
intracranial pressure monitoring

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2023-11-13 with a primary completion date of 2026-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The new Integra CereLink ICP monitor integrate the possibility of recording and displaying continuously the AUC (Pressure Time Dose, PTD) and other ICP derived variables and provide the possibility of evaluating the utility of this information at the bedside. It offers the opportunity to test in a standardized way the clinical value of the PTD computation in this setting. Therefore, this study aims to test clinically if PTD recorded continuously is associated to patients' outcome and to identify a threshold of PTD associated with the transition from good to negative outcomes.

Eligibility Criteria

Inclusion Criteria: * Aged within 18 and 80 years; * Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury; * ICP monitoring started for clinical indication and accordingly to local policies * ICP device connected to the Integra CereLink ICP monitor. Exclusion Criteria: * ICP monitoring not inserted * No availability of the Integra CereLink ICP monitor.

Contact & Investigator

Central Contact

Giuseppe Citerio, Professor

✉ giuseppe.citerio@unimib.it

📞 +39039233

Principal Investigator

Giuseppe Citerio, Professor

PRINCIPAL INVESTIGATOR

University of Milano Bicocca

Frequently Asked Questions

Who can join the NCT04459806 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Intracranial Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04459806 currently recruiting?

Yes, NCT04459806 is actively recruiting participants. Contact the research team at giuseppe.citerio@unimib.it for enrollment information.

Where is the NCT04459806 trial being conducted?

This trial is being conducted at Monza, Italy.

Who is sponsoring the NCT04459806 clinical trial?

NCT04459806 is sponsored by University of Milano Bicocca. The principal investigator is Giuseppe Citerio, Professor at University of Milano Bicocca. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology